Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 27, 2023, titled "Eugia Pharma receives USFDA Approval for Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 27, 2023, titled "Eugia Pharma receives USFDA Approval for Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial".